Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP
Status:
Not yet recruiting
Trial end date:
2027-09-20
Target enrollment:
Participant gender:
Summary
This study is a single-arm, single-center exploratory clinical study. Twenty patients with
early-stage HER2-positive breast cancer are planned to be included, and the primary objective
is to evaluate the efficacy of neoadjuvant regimen of Pyrotinib in combination with
trastuzumab + pertuzumab.